Pharma Medical Affairs & Compliance · Healthcare & Life Sciences
Should you build or buy Pharma MLR / Promotional Material Review (PromoMats)?
Pharma MLR / Promotional Material Review software (commonly called PromoMats) manages the medical-legal-regulatory review cycle for promotional and medical content, tracking claims against approved label language, enforcing fair-balance requirements, versioning materials through review stages, and generating the audit trail required for FDA 2253 submissions.
The build-vs-buy decision for Pharma MLR / Promotional Material Review turns on whether the AI pre-screening layer — which teams are already running in production at a fraction of full platform costs — can be separated from the compliance documentation infrastructure that FDA 2253 submission and inspection readiness require; the proportion of your cost that lives in review labor versus audit-trail infrastructure decides it.
Build it, buy it, or bridge?
When building makes sense
Building part of this workflow is not hypothetical — pharma companies are running LLM-based MLR pre-screening tools in production today, catching 70 to 85 percent of promotional review issues before material reaches a human reviewer. The claim-checking logic, comparing promotional language against approved label claims and fair-balance requirements, is well-scoped enough for LLM deployment. Teams with high promotional content volume and LLM engineering capacity can get meaningful per-review cost reductions from an internal AI pre-screening layer. The realistic build scope is that intelligence layer, not the full MLR system. FDA 2253 submission logistics and the audit trail that inspection readiness requires still favor purpose-built platforms. The most cost-effective architecture emerging in the industry separates these two concerns: custom AI for claim pre-screening, maintained vendor platform for the compliance documentation and submission infrastructure.
When buying makes sense
Buying remains compelling when compliance documentation integrity is the primary concern and the cost of a regulatory gap is higher than the cost of the platform. Platforms like Veeva Vault PromoMats and Vodori Pepper Flow carry pre-validated review workflows, version control, and the audit trail that FDA expects to see during a promotional review inspection. If your team doesn't have LLM engineering resources, or your promotional volume doesn't justify the investment in a custom pre-screening tool, a full platform is the faster path to a defensible compliance posture. The 60 to 80 percent of platform features that are actively used — review workflow, versioning, audit trail — are genuinely useful, not shelfware. The risk calculus also shifts toward buying when enforcement risk is elevated, such as around a new product launch or following a Warning Letter.
The desk read
AI pre-screening of promotional claims against label language is in production at multiple pharma companies right now, not in pilot. Teams are running LLM-based review tools that catch 70 to 85 percent of MLR issues before material reaches a human reviewer, at a fraction of the per-review cost of full Veeva Vault PromoMats licensing. That's not a theoretical future state; it's a documented operational shift that's changing the vendor value calculation.
Buying still earns its keep on the audit trail and FDA 2253 submission logistics. Platforms like Veeva Vault PromoMats or Vodori Pepper Flow provide the compliance documentation infrastructure that MLR review must generate, and those requirements aren't going away. The question is whether the AI intelligence layer and the compliance infrastructure layer need to come from the same vendor. Companies that separate them, building AI pre-screening internally while maintaining a lighter-weight platform for audit trail and submission, are finding meaningfully lower total cost without sacrificing compliance coverage.
Frequently asked
What is Pharma MLR / Promotional Material Review (PromoMats) software?
Pharma MLR / Promotional Material Review software manages the medical-legal-regulatory review cycle for promotional and medical content, tracking claims against approved label language, enforcing fair-balance requirements, versioning materials through review stages, and generating the audit trail required for FDA 2253 submissions.
When does building Pharma MLR / Promotional Material Review make sense?
Building the AI pre-screening layer is viable right now — teams are running LLM-based claim-checking tools in production that catch 70 to 85 percent of MLR issues at a fraction of full platform costs. The realistic build scope is the intelligence layer; the compliance audit trail and FDA submission infrastructure still favor vendor platforms.
When does buying Pharma MLR / Promotional Material Review make sense?
Buying is right when compliance documentation integrity is the priority, your team lacks LLM engineering resources, or your promotional volume doesn't justify building custom AI pre-screening. Established platforms carry pre-validated workflows and audit trail infrastructure designed for FDA inspection readiness.
What are the main Pharma MLR / Promotional Material Review vendors?
Representative vendors include Veeva Vault PromoMats, Indegene (NEXT MLR), Vodori (Pepper Flow), Papercurve. B4 Pro scores the full set.
What is the difference between MLR review and AI pre-screening in pharma?
MLR review is the full medical-legal-regulatory sign-off cycle that promotional materials go through before release, including human review by medical, legal, and regulatory functions. AI pre-screening is an upstream filter that runs promotional claims against label language automatically, flagging likely issues before material reaches the human review queue. Companies are increasingly running these as separate layers, using AI pre-screening to reduce the volume hitting full MLR review.